{"id":53420,"date":"2023-01-30T16:02:50","date_gmt":"2023-01-30T15:02:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/"},"modified":"2023-01-30T16:02:50","modified_gmt":"2023-01-30T15:02:50","slug":"valent-biosciences-announces-the-acquisition-of-fbsciences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/","title":{"rendered":"Valent BioSciences Announces the Acquisition of FBSciences"},"content":{"rendered":"
\n

LIBERTYVILLE, Ill.–(BUSINESS WIRE)–Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions. With this acquisition, Valent BioSciences and its parent company, Sumitomo Chemical Co., Ltd., now offer an innovative and proven portfolio of integrated biorational solutions, including biostimulants, biopesticides, and crop nutrition solutions.\n<\/p>\n

<\/a><\/p>\n

\nThe acquisition of FBSciences, a recognized leader in biostimulants headquartered in Collierville, Tennessee, greatly strengthens Valent BioSciences\u2019 participation in the rapidly growing $3.5 billion global biostimulant market. On October 1, 2022, Valent BioSciences began selling biostimulant products directly to its U.S. customer base. This acquisition will provide a significant growth platform for the two companies\u2019 wide range of crop enhancement and crop protection products and forms a key pillar in the overall business strategy.\n<\/p>\n

\nFBSciences\u2019 portfolio of biorational technologies is naturally derived, renewable, and sustainable, and forms the foundation of a wide offering of innovative solutions for agriculture. The company\u2019s core technologies are derived from natural organic matter (NOM) utilizing proprietary production processes that target and extract a diverse mixture of unique and biologically active compounds that transform plant, soil, and climate health. With a science-based approach and decades of research, FBSciences delivers powerful technologies and products with a track record of superior performance and proven commercial success.\n<\/p>\n

\nThe company\u2019s flagship biostimulant technology, FBS Transit\u00ae<\/sup>, forms the foundation of its crop nutrition and nutrient use efficiency product lines for use on all crops. It works inside the plant to increase the uptake and translocation of all nutrients, leading to healthier plants that can withstand stress, which results in increased yields and quality.\n<\/p>\n

\nFBSciences\u2019 biopesticide technology, FBS Defense\u2122, works within the plant to increase its ability to defend itself from biotic stresses, including insects and diseases, and increases harvestable yields.\n<\/p>\n

\nBoth companies are well recognized for their industry-leading research and development capabilities, which will spark rapid innovation and commercialization of new technologies and products to deliver substantial growth for the biorationals arena.\n<\/p>\n

\n\u201cThe acquisition of FBSciences is a natural next step in the evolution of our organization as a global leader in biorationals, including biostimulants,\u201d said Ted Melnik, President and CEO of Valent BioSciences. \u201cOur combined organizations have many decades of experience leading our respective markets with science-based technology and innovation. The wide range of biostimulant, biopesticide, and crop nutrition products and technologies in the FBSciences portfolio augments Valent BioSciences\u2019 broad family of biorational products, thereby creating an unmatched range of value-added and sustainable solutions that no other company can provide.\u201d\n<\/p>\n

\nSumitomo Chemical has pledged to achieve carbon neutrality by 2050, aiming to reduce the amount of greenhouse gases emitted by its production and business activities. \u201cValent BioSciences\u2019 keen focus on developing products that sequester atmospheric carbon, combined with FBSciences\u2019 technologies, will help accelerate this effort,\u201d said Nobuaki Mito, Director and Senior Managing Executive Officer of Sumitomo Chemical. \u201cThis acquisition will step forward our Green Transformation strategy initiatives and contribute to realizing sustainable agriculture and society in the future.\u201d\n<\/p>\n

\n\u201cThe acquisition of FBSciences by Valent BioSciences is a major leap forward for the biorational industry,\u201d said Courtenay Wolfe, CEO and Chairwoman of FBSciences. \u201cThis tremendous milestone for FBSciences recognizes 16 years of success developing and commercializing transformative plant, soil, and climate health solutions. Our companies share a common rooted-in-science approach coupled with a mission to better society and our planet. Adding FBSciences\u2019 expertise, innovative solutions, and entrepreneurial spirit to Valent BioSciences\u2019 global powerhouse of resources and robust solutions will deliver a platform unrivaled in the industry and continue to propel Valent BioSciences\u2019 leadership position in the rapidly growing biorational space.\u201d\n<\/p>\n

\nAbout Valent BioSciences LLC<\/b>\n<\/p>\n

\nHeadquartered in Libertyville, Illinois, Valent BioSciences is a subsidiary of Tokyo-based Sumitomo Chemical Co., Ltd., and is the worldwide leader in the development, manufacturing, and commercialization of biorational products, with sales in 95 countries around the world. Valent BioSciences is an ISO 9001 Certified Company. For additional information, visit the company\u2019s website at www.valentbiosciences.com<\/a>.\n<\/p>\n

\nAbout FBSciences Holdings, Inc.<\/b>\n<\/p>\n

\nFBSciences is a global leader in the innovation and commercialization of climate-smart biorationals for agriculture. The company\u2019s naturally derived, proprietary technologies are the foundation for its biostimulant, biopesticide, and crop nutrition product lines. FBSciences has proven that its technologies and products increase quality and nutrient density, improve stress mitigation and recovery, produce healthier plants and higher yields, and increase utilization of other crop inputs. In addition, the company\u2019s sustainable products provide measurable benefits to the environment, including increased nitrogen use efficiency, leading to N2<\/sub>O emissions reduction, decreased nitrogen runoff, and reduced CO2<\/sub> emissions by increased carbon sequestration. With an opportunity for meaningful impact on every managed acre, FBSciences is committed to harnessing the power of nature to transform agriculture globally. For additional information, visit the company\u2019s website at www.fbsciences.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJohn Mandel
\n
Valent BioSciences LLC
\n
847-968-4728
\n
Email: john.mandel@valentbiosciences.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LIBERTYVILLE, Ill.–(BUSINESS WIRE)–Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions. With this … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53420","6":"format-standard","7":"category-industry"},"yoast_head":"\nValent BioSciences Announces the Acquisition of FBSciences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valent BioSciences Announces the Acquisition of FBSciences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LIBERTYVILLE, Ill.–(BUSINESS WIRE)–Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions. With this ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T15:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230130005421\/en\/669932\/21\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Valent BioSciences Announces the Acquisition of FBSciences\",\"datePublished\":\"2023-01-30T15:02:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/\"},\"wordCount\":842,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005421\\\/en\\\/669932\\\/21\\\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/\",\"name\":\"Valent BioSciences Announces the Acquisition of FBSciences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005421\\\/en\\\/669932\\\/21\\\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg\",\"datePublished\":\"2023-01-30T15:02:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005421\\\/en\\\/669932\\\/21\\\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005421\\\/en\\\/669932\\\/21\\\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/valent-biosciences-announces-the-acquisition-of-fbsciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valent BioSciences Announces the Acquisition of FBSciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valent BioSciences Announces the Acquisition of FBSciences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/","og_locale":"en_US","og_type":"article","og_title":"Valent BioSciences Announces the Acquisition of FBSciences - Pharma Trend","og_description":"LIBERTYVILLE, Ill.–(BUSINESS WIRE)–Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions. With this ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-30T15:02:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230130005421\/en\/669932\/21\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Valent BioSciences Announces the Acquisition of FBSciences","datePublished":"2023-01-30T15:02:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/"},"wordCount":842,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005421\/en\/669932\/21\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/","url":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/","name":"Valent BioSciences Announces the Acquisition of FBSciences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005421\/en\/669932\/21\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg","datePublished":"2023-01-30T15:02:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230130005421\/en\/669932\/21\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230130005421\/en\/669932\/21\/Valent_Bio_Logo_Hi_Resolution_NoBackground.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/valent-biosciences-announces-the-acquisition-of-fbsciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Valent BioSciences Announces the Acquisition of FBSciences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53420"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53420\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}